The company had posted a net profit of USD 33.1 million in the year-ago period, it said in a statement.
Revenues rose by 10.7 per cent to USD 331.5 million in the October-December quarter of 2014 fiscal from USD 299.3 million in the same quarter in 2013. The figures are on GAAP basis.
Commenting of the performance, IGATE President and CEO Ashok Vemuri said: "We delivered growth both sequentially as well as year over year, a result of the differentiated industry utility-solutions, enhanced client-centricity, streamlining of our core execution, building next-gen capabilities, and committed iGATORs."
The firm added nine new clients during the December quarter. Total headcount stood at 33,484 employees.
Also Read
The firm said its GAAP diluted EPS (Earnings Per Share) includes USD 80 million paid to Series B preferred stock holders for the induced conversion and USD 1.7 million towards write-off of unamortised preferred stock issuance cost.
According to analysts, the firm's revenue growth matches industry growth standard.
Greyhound research CEO Sanchit Vir Gogia said: "We believe that the sequential revenue growth of 2.7 per cent is as per industry standards. IGATE's main strengths are in Healthcare, FSI and Manufacturing sector."
"Also, with NHS in the UK going the privatisation way soon, we believe that huge investments are expected to happen then and this surely puts iGate in a very well placed and profitable spot," he added.
For the entire 2014 fiscal, IGATE's net profit fell by 15 per cent to USD 110 million against USD 129.8 million in 2013 fiscal. Revenues rose by 10.2 per cent to USD 1.26 billion from USD 1.15 billion during the same period.
The company added 29 new clients during the year and its employee additions (net) stood at 3,751.